相关实验视频
Updated: May 10, 2026
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
一种工程双价神经素可以保护人免受多克索鲁比诱导的心脏毒性,并降低了前原形成潜力
Steven M Jay1, Ashwin C Murthy, Jessica F Hawkins
1Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA.
Circulation
|June 13, 2013
概括
一种新研制的神经调节素-1β (NN) 配方显示,它有望防止多克索鲁比 (DOXO) 诱导的心脏损伤. 这种新型药物改善心脏功能,促进心肌细胞存活,为癌症患者提供潜在的心脏保护策略.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 多克索鲁比 (DOXO) 化疗导致剂量依赖的心脏毒性,限制其使用.
- 神经调节素-1β (NRG) 显示对DOXO诱导心肌病的有效性,但具有前性潜力.
- 设计的双价神经调节素-1β (NN) 通过偏向受体相互作用,证明了减少了proneoplastic效应.
研究的目的:
- 与NRG.相比,研究一种新配方的共价NN的心脏保护和proneoplastic作用.
- 评估NN在减轻DOXO诱导心脏毒性的有效性.
主要方法:
- 在NN中,NN表达为一种马尔托结合蛋白融合.
- 评估了癌细胞信号传递和心肌细胞对NN和NRG的反应.
- 在小鼠模型中,DOXO诱导心肌病,心脏功能通过心声回声仪测量.
主要成果:
- 在癌细胞中,NN显示出抗瘤信号,而NRG显示出前瘤信号.
- 在心肌细胞中,NN和NRG都减弱了DOXO诱导的DNA断裂.
- 在DOXO诱导心肌病的小鼠模型中,NN显著改善了心脏分数缩短,而NRG没有.
结论:
- 在DOXO诱导的心脏毒性背景下,NN作为心脏保护剂,增强心肌细胞存活率和心脏功能.
- 与NRG相比,NN显示出较低的前新生体潜力.
- 在接受 antracycline 治疗的癌症患者中,NN 具有心脏保护的翻译潜力.
相关概念视频
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...